Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Canadian Centre on Substance Abuse, the most common co-covered peer. The tracked stories average 3 original sources each. Ontario Drug Strategy appears in 1 tracked Biotech story from August 9, 2026.
Last mentioned: Aug 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Canadian Centre on Substance Abuse, the most common co-covered peer. The tracked stories average 3 original sources each. Ontario Drug Strategy appears in 1 tracked Biotech story from August 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ontario Drug Strategy. Shared-story counts are live from our verified record — not editorial picks.
Reggie Caverson’s new book details how OxyContin was prescribed for 15 years without guidelines in Canada, underscoring the biopharmaceutical industry’s role in overselling a high-abuse-risk product. Her narrative demands stricter post-market surveillance and more transparent marketing practices for all novel pain therapeutics.
Source: thesudburystar.com · elliotlakestandard.ca
Ontario Drug Strategy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
